| Name | PMX 205 acetate(514814-49-4 free base) |
| Description | PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88). |
| In vitro | PMX 205 (PMX205) group is in between 0.09893 to 0.2465, EP54 group, 0.02724 to 0.1748 and Tamoxifen group, the value recorded in between 0.09880 to 0.2464. For the 48 h plate of incubation time, only two groups of PMX 205 and Tamoxifen show a significant result. The values recorded are in between 0.04987 to 0.3273 and 0.5777 to 0.8551 respectively. For the 72 h plate, only one group shows a significant result, PMX 205 (antagonist group) with the value recorded in between 0.02136 to 0.5322[1]. |
| In vivo | Tg2576 mice are treated with PMX 205 (PMX205) at 20 μg/mL in the drinking water (n=17) from 12 to 15 mo of age, the time frame at which there is a rapid accumulation of amyloid deposits in these animals. Untreated Tg2576 animals (n=11) are used as controls. After 3 mo, animals treated with PMX 205 show significantly less fibrillar plaque load (thioflavine reactivity) than do untreated animals. In 3×Tg mice, PMX 205 also significantly reduces hyperphosphorylated tau (69%)[2]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/ml (66.73 mM)
|
| Keywords | PMX 205 acetate(514814494 free base) | PMX 205 acetate(514814 49 4 free base) | PMX 205 acetate(514814-49-4 free base) |
| Inhibitors Related | Iptacopan hydrochloride | Dexamethasone | Cyclosporin A | 3-Phenoxybenzaldehyde |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max |
United States
